1. Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol. 2016;46(9):2078-90. [
DOI:10.1002/eji.201646485] [
PMID]
2. Jamali M, Rostami Rad M, Anani Sarab G, Mahdavi R. IL-33 polymorphism rs1929992 and its association with susceptibility to different pattern of multiple sclerosis. Tehran Univers Med J. 2018;76(7):446-451.
3. Klaren RE, Sasaki JE, McAuley E, Motl RW, Health. Patterns and predictors of change in moderate-to-vigorous physical activity over time in multiple sclerosis. J Phys Act Health. 2017;14(3):183-188. [
DOI:10.1123/jpah.2016-0335] [
PMID]
4. Csepany T. Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria. Ideggyogyaszati szemle. 2018;71(9-10):321-329. [
DOI:10.18071/isz.71.0321] [
PMID]
5. Pan Y, Wang K-S, Wang L, Wu L-Y. Common Variants in HLA-DRA Gene are Associated with Alcohol Dependence in Two Caucasian Samples. J Mol Neurosci. 2013;49(3):574-81. [
DOI:10.1007/s12031-012-9869-3] [
PMID]
6. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36. [
DOI:10.1038/nrneurol.2016.187] [
PMID]
7. Berge T, Leikfoss I, Brorson I, Bos S, Page C, Gustavsen M, et al. The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells. Genes Immun. 2016;17(2):118-27. [
DOI:10.1038/gene.2015.61] [
PMID] [
PMCID]
8. Fang P, Schachner M, Shen Y-Q. HMGB1 in development and diseases of the central nervous system. Mol Neurobiol. 2012;45(3):499-506. [
DOI:10.1007/s12035-012-8264-y] [
PMID]
9. Malhotra S, Fissolo N, Tintoré M, Wing AC, Castillo J, Vidal-Jordana A, et al. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. J Neuroinflammation. 2015;12:48. [
DOI:10.1186/s12974-015-0269-9] [
PMID] [
PMCID]
10. Zhen C, Wang Y, Li D, Zhang W, Zhang H, Yu X, et al. Relationship of High-mobility group box 1 levels and multiple sclerosis: A systematic review and meta-analysis. Mult Scler Rel Disord. 2019;31:87-92. [
DOI:10.1016/j.msard.2019.03.030] [
PMID]
11. Andersson Å, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol. 2008;84(5):1248-55. [
DOI:10.1189/jlb.1207844] [
PMID]
12. Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F. Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls. Cells. 2019;8(6):634. [
DOI:10.3390/cells8060634] [
PMID] [
PMCID]
13. Wang S, Zhai H, Su Y, Wang Y. IL-17F but not IL-17A gene polymorphism confers risk to multiple sclerosis in a Chinese Han population. Journal of the Neurological Sciences. 2014;342(1-2):133-136. [
DOI:10.1016/j.jns.2014.05.004] [
PMID]
14. Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CH, et al. snP Variants in Major histocompatibility complex are associated with sarcoidosis susceptibility-a Joint analysis in Four european Populations. Front Immunol. 2017;8:422. [
DOI:10.3389/fimmu.2017.00422] [
PMID] [
PMCID]
15. Mentzer AJ, Brenner N, Allen N, Littlejohns TJ, Chong AY, Cortes A, et al. Identification of host-pathogen-disease relationships using a scalable Multiplex Serology platform in UK Biobank. medRxiv. 2019:19004960. [
DOI:10.1101/19004960]
16. Mahmud SA, Manlove LS, Farrar MA. Interleukin-2 and STAT5 in regulatory T cell development and function. JAKSTAT. 2013;2(1):e23154. [
DOI:10.4161/jkst.23154] [
PMID] [
PMCID]
17. Afanasyeva MA, Putlyaeva LV, Demin DE, Kulakovskiy IV, Vorontsov IE, Fridman MV, et al. The single nucleotide variant rs12722489 determines differential estrogen receptor binding and enhancer properties of an IL2RA intronic region. PLoS One. 2017;12(2):e0172681. [
DOI:10.1371/journal.pone.0172681] [
PMID] [
PMCID]
18. Cavanillas ML, Alcina A, Núñez C, De Las Heras V, Fernández-Arquero M, Bartolomé M, et al. Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. European Journal of Human Genetics. 2010;18(7):794-799. [
DOI:10.1038/ejhg.2010.15] [
PMID] [
PMCID]
19. Erlandsson Harris H, Andersson U. Mini‐review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004;34(6):1503-12. [
DOI:10.1002/eji.200424916] [
PMID]
20. Friggeri A, Yang Y, Banerjee S, Park Y-J, Liu G, Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the αvβ3-integrin. Am J Physiol Cell Physiol. 2010;299(6):C1267-C1276. [
DOI:10.1152/ajpcell.00152.2010] [
PMID] [
PMCID]
21. Ek M, Popovic K, Erlandsson Harris H, Söderberg Nauclér C, Wahren‐Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 2006;54(7):2289-94. [
DOI:10.1002/art.21969] [
PMID]